HIV-1 protease-IN-6
HIV-1 protease-IN-6 (compound 17d) is a potent HIV-1 protease inhibitor, with an IC50 of 21 pM and a Ki of 4.7 pM, respectively. HIV-1 protease-IN-6 exhibits potent antiviral activity to DRV (darunavir)-resistant variant, even more than wild type virus.
For research use only. We do not sell to patients.
- CAS No.: 2892016-32-7
- Formula: C27H31FN2O6S
- Molecular Weight:530.61
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
HIV-1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | CC50 |
>100 μM
Compound: 17d
|
Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
|
[PMID: 35483138] |
| SUP-T1 | EC50 |
0.74 μM
Compound: 17d
|
Antiviral activity against wild-type HIV1 NL4-3 VSV-G pseudotyped virus infected in human SUP-T1 cells assessed as inhibition of late stage viral production pretreated with viral infected SUP-T1 cells for 48 hrs followed by reinfection in TZM-bl cells by
Antiviral activity against wild-type HIV1 NL4-3 VSV-G pseudotyped virus infected in human SUP-T1 cells assessed as inhibition of late stage viral production pretreated with viral infected SUP-T1 cells for 48 hrs followed by reinfection in TZM-bl cells by
|
[PMID: 35483138] |
In Vitro
HIV-1 protease-IN-6 (compound 17d) (10 μM; 48 h) exhibits full inhibition against the late stage of HIV-1 replication cycle while the inhibition rate is 2.6% on early stage at the cellular level[1].
HIV-1 protease-IN-6 (10 μM; 24 h) displays antiviral activity against HIV-1NL4-3 with an EC50 value of 0.74 μM, and exhibits anti-DRV-resistant tendency with an EC50 value of 0.61 μM towards DRV-resistant variant[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 2892016-32-7
-
Molecular Weight 530.61
-
Formula C27H31FN2O6S
-
SMILES
CC(CN(S(=O)(C1=CC=C(C=C1)F)=O)C[C@H]([C@@H](NC(C2=CC(O)=CC(O)=C2)=O)CC3=CC=CC=C3)O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)